INTRODUCTION
Arsenic contamination of groundwater has led to a massive epidemic of arsenic poisoning in Bangladesh and neighboring countries. It is estimated that approximately 57 million people are drinking groundwater with arsenic concentration elevated above the World Health Organization's standard of 10 parts per billion (Uddin and Huda, 2011) . Arsenic contamination of ground water in context to Bangladesh is well documented (Uddin and Huda, 2011; Uddin et al., 2012) . Chronic arsenic exposure is associated with many human health conditions, including skin lesions and cancers of the liver, lung, bladder and skin . It is also associated with many non-cancer health effects, such as adverse reproductive outcomes, neurological disorders, and impaired cognitive development in children (Wasserman et al., 2004) . Paracetamol is a common analgesicantipyretic drug which has been included in the 15 th model list of essential medicines by WHO as nonopioids and nonsteroidal anti-inflammatory medicines (NSAIMs) (WHO 2007) . The drug is thought to be one of the safest drugs. But toxicity associated with this drug is also common. Paracetamol toxicity results when it is taken at very large doses (Dong et al., 2000) . Paracetamol overdose results in more calls to poison control centers in the USA than overdose of any other pharmacological substance, accounting more than 100,000 calls, as well as 56,000 emergency room visits, 2,600 hospitalizations and 458 deaths due to acute liver failure per year (Lee, 2004) . A recent study of cases of acute liver failure between November 2000 and October 2004 by the Center for Disease Control and Prevention (US) found that paracetamol was the cause of 41% of all cases in adults and 25% of cases in children (Bower et al., 2007) . As paracetamol is widely available, there is a large potential for overdose and toxicity (Sheen et al., 2002 The reduction in the extent of binding of a drug to protein occurred by the presence of other drug is termed as drug-drug interaction or drug displacement which may increase the free concentration of the displaced drug and may lead to higher pharmacological as well as toxic effects (Rahman et al., 1993) . Keeping these considerations in mind paracetamol, a commonly used non-steroidal antiinflammatory drug has been investigated to determine the effect of arsenic on the binding of the drugs at the binding sites of bovine serum albumin. Method used: Equilibrium dialysis was employed in the study (Singlas, 1987) .
MATERIALS AND METHODS
Site-specific probes method: Different site-specific probes have been used to enhance the understanding of the drug-BSA interaction and thereby characterization of binding sites of the drugs used in the study on the BSA molecule (Sudlow et al., 1975; Sudlow et al., 1976; Singlas, 1987) . Two site-specific probes were used; warfarin sodium (site I-specific probe) and diazepam (site II-specific probe) for the identification of the binding sites of the drugs on BSA. In the direct procedure, the ratio of BSA and probe (either warfarin or diazepam) was 1:1 (2×10 -5 M: 2×10 -5 M), and different concentrations of drug were added. In the reverse procedure, the ratio of BSA and drug was 1:1 (2×10 -5 M: 2×10 -5 M), and different concentrations of probe (Site I-specific warfarin sodium or Site IIspecific diazepam) were added. After conducting equilibrium dialysis, the free concentrations of probe were determined in direct procedure and reverse procedure respectively.
Standard curve preparation: Standard curve was prepared by using the various concentrations and their corresponding absorbance at pH 7.4. UV spectrophotometric scanning of the drug paracetamol showed maximum absorbance of the UV light at 246 nm. Paracetamol has found linearity at a concentration of 10-80µM/ml with a confidence level of 0.9995 at pH 7.4 with linear equation Y= 0.0911X+0.0003 which was used to calculate the concentration of the drug being investigated.
Effect of arsenic on paracetamol bound to BSA in absence of site specific probes 3.0 ml of previously prepared 2×10 -5 M BSA solution was taken in each of seven previously cleaned and dried test tubes. 6 µL of 1×10 -2 M paracetamol solution was taken in each of six cleaned and dried test tubes. The final ratio between protein and drug was 1:1 (2×10 -5 M: 2×10 -5 M) in each of six test tubes. The seventh test tube containing only BSA was marked as blank. Arsenic was added with an increasing concentration in five out of six test tubes containing 1:1 mixture of protein and drug to make the final ratio of protein, paracetamol and arsenic 1:1:0, 1:1:1, 1:1:2, 1:1:4, 1:1:6 and 1:1:8. Arsenic was not added to one test tube. The solution mixture was then properly mixed and allowed to stand for 15 minutes for the confirmation of maximum binding to BSA. After 15 minutes the solutions were pipetted out and poured into seven different semipermeable membrane tubes. Both the end of the membrane was clipped and was ensured that there was no leakage. The tubes containing drug mixture were immerged in seven 50 ml conical flasks containing 30 ml of phosphate buffer solution at pH 7.4. The conical flasks were then placed in a mechanical shaker and were shacked at 27°C temperature with 20 rpm continuously for six hours uninterruptedly to complete the dialysis. After shaking is complete samples were collected from each flask. Free concentrations of paracetamol were measured by using a UV-VIS spectrophotometer at a wavelength of 246 nm.
Effect of arsenic on paracetamol bound to BSA in presence of site I and site II specific probes Warfarin Sodium and Diazepam respectively 3.0 ml of previously prepared 2×10 -5 M BSA solution was taken in each of seven previously cleaned and dried test tubes. 12 µL of 1×10 -2 M warfarin sodium solution was taken in each of six cleaned and dried test tubes. The final ratio between protein and warfarin was 1:2 (2×10 -5 M: 4×10 -5 M) in each of six test tubes. Then the site-I was sufficiently blocked by site-I specific probe. The seventh test tube containing only BSA solution was marked as blank. Paracetamol was added in five out of six test tubes so that protein, warfarin and paracetamol ratio becomes 1:2:1 (2×10 -5 M: 4×10 -5 M: 2×10 -5 M). Arsenic was added with an increasing concentration into four out of five test tubes containing 1:2:1 mixture of protein-warfarin-paracetamol to make the final ratio of protein, warfarin, paracetamol and arsenic 1:2:1:0, 1:2:1:1. 1:2:1:2, 1:2:1:4, 1:2:1:6. Arsenic was not added to one test tube. The solution mixture was then properly mixed and allowed to stand for 15 minutes for the confirmation of maximum binding to BSA. After 15 minutes the solutions were pipetted out and poured into seven different semi-permeable membrane tubes. Both the end of the membrane was clipped and was ensured that there was no leakage. The tubes containing drug mixture were immerged in seven 50 ml conical flasks containing 30 ml of phosphate buffer solution at pH 7.4. The conical flasks were then placed in a mechanical shaker and were shacked at 27°C temperature with 20 rpm continuously for six hours uninterruptedly to complete the dialysis. After shaking is complete samples were collected from each flask. Free concentrations of paracetamol were measured by using a UV-VIS spectrophotometer at a wavelength of 246 nm. The same procedure was followed when site II specific probe Diazepam was used.
RESULT AND DISCUSSION
Effect of arsenic on paracetamol binding to BSA in absence and in presence of site I and site II specific probes are shown in Figure 1 . From the data analyzed different model of interaction between arsenic-paracetamol is proposed and presented at Figure 2 either in presence of site specific probes or in absence of site specific probes. The effect of arsenic on paracetamol in absence and in presence of site-I specific probe warfarin and site-II specific probe diazepam are shown in Figure 1 . Free concentrations of paracetamol bound to BSA upon the addition of arsenic in absence of any of the two site specific probes was increased from 3.95 ± 1.164% to 25.36 ± 1.164% when arsenic to BSA ratio was increased from 1:1 to 1:8. In presence of site-I specific probe warfarin sodium the % release of drug was found to be steady at around 14%. But in presence of diazepam; site-II specific probe an increment of free drug concentration was observed (free paracetamol concentration increased from 14.38 ± 1.164% to 54.72 ± 1.552% when arsenic to BSA ratio increased from 1:1 to 1:8).
Thus we can speculate that the free concentration of paracetamol was increased to a greater extent in presence of arsenic and probably arsenic bound to site-II of BSA. In presence of site-I specific probe the effect of arsenic was not significant. So, arsenic may displace paracetamol by binding with high affinity binding site, site-II in the BSA and probably arsenic has little effect to site-I. According to Uddin et al. (2004) , site I (warfarin site) is low affinity site while site-II (diazepam site) is high affinity site of arsenic to BSA binding. The findings from this current study complied with Uddin et al. in respect to arsenic-paracetamol binding pattern. 
The ability of one drug to inhibit the other is a function of their relative concentration, binding affinities and specificity of binding (Koch-Weser and Sellers, 1976) . Since only a small fraction of drug would ordinarily be available in the free form, the displacement of even a small percentage of the amount of drug that is bound to proteins could produce considerable increase in activity (Uddin et al., 2005) . In case of drug-drug interaction with arsenic the possibility of the occurrence of site to site displacement should also be considered as there will be a difference between the free concentration of a displaced drug with or without site to site displacement. Moreover, protein binding of a drug is not a phenomenon particular to plasma.
As per our findings in this study, it has been observed that arsenic increased the free drug concentration of paracetamol. It may lead to excessive pharmacological action of the said drug which may lead to toxicity and even paracetamol poisoning. In a previous study we found that the presence of arsenic warfarin is slowly displaced from its high affinity binding site with increasing paracetamol concentration (Alam et al., 2008) . Paracetamol is associated with an increased hypoprothrombinemic effect of warfarin. This interaction was proposed due to inhibition of its metabolism and interference with formation of clotting factors. Gingival bleeding and hematuria were observed when paracetamol was given with warfarin (Hylek et al., 1998) . Several case reports including case controlled studies have reported that paracetamol potentiates the anti-coagulant effect of warfarin (Andrews, 2002) , others have not found a clinically relevant interaction (Fattinger et al., 2002) . NSAIDs such as mefenamic acid (Holemes, 1966) , etodolac (Ermer et al., 1994) , ibuprofen (Penner and Abdrecht, 1975; Schulman and Henriksson, 1989) and tenidap (Apseloff et al., 1995) may also displace coumarin anti-coagulants from protein binding sites.
CONCLUSIONS
Considering all these aspects, facts and findings it can be concluded that the patients who are affected by arsenic should be careful of using NSAIDs. And the physicians should ensure therapeutic drug monitoring in case of prescribing NSAIDs to arsenic affected population. Proper care should be taken during prescribing paracetamol as it is evident from our study that arsenic potentially changes the pharmacokinetics of the drug during concurrent administration of arsenic and the drug.
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